Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis

Chiari, Rita; Metro, Giulio; Iacono, Daniela; Bellezza, Guido; Rebonato, Alberto; Dubini, Alessandra; Sperduti, Isabella; Bennati, Chiara; Paglialunga, Luca; Burgio, Marco Angelo; Baglivo, Sara; Giusti, Raffaele; Minotti, Vincenzo; Delmonte, Angelo; Crinò, Lucio

doi:10.1016/j.lungcan.2015.09.009

Cited by 45 publications

(34 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published retrospective analysis of 73 patients treated with crizotinib then ceritinib reported a 49.4-month OS from diagnosis of metastatic disease, though did not provide a comparator population [20]. Two smaller studies with 11 and 13 patients treated with crizotinib then reported good survival outcomes [21, 22]. In our study, the 84 patients receiving next-generation ALKis after crizotinib achieved an 89.6-month OS from diagnosis of metastatic disease, with a 59.2% 3-year survival from the first crizotinib dose and median post-PD survival of 25.0 months.…”

Section: Discussionmentioning

confidence: 99%

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

et al. 2017

View full text Add to dashboard Cite

Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in a large population of unselected patients with ALK-positive non-smallcell lung cancer (NSCLC) is not documented. We sought to assess OS with crizotinib in unselected ALK-positive NSCLC patients and whether post-progression systemic treatments affect survival outcomes.ALK-positive NSCLC patients receiving crizotinib in French expanded access programs or as approved drug were enrolled. We collected clinical and survival data, RECIST-defined progressive disease (PD) and post-PD systemic treatment efficacy. We performed multivariable analysis of OS from crizotinib initiation and PD under crizotinib. Unselected ALK-positive NSCLC patients achieve good survival outcomes with crizotinib therapy. Next-generation ALKi may provide survival improvement after PD under crizotinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Due to these developments, several ALK‐TKI are used sequentially in clinical practice at present . However, disease progression due to acquired resistance inevitably occurs after several years, resulting in a major problem in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

et al. 2020

View full text Add to dashboard Cite

The treatment for anaplastic lymphoma kinase (ALK)‐positive lung cancer has been rapidly evolving since the introduction of several ALK tyrosine kinase inhibitors (ALK‐TKI) in clinical practice. However, the acquired resistance to these drugs has become an important issue. In this study, we collected a total of 112 serial biopsy samples from 32 patients with ALK‐positive lung cancer during multiple ALK‐TKI treatments to reveal the resistance mechanisms to ALK‐TKI. Among 32 patients, 24 patients received more than two ALK‐TKI. Secondary mutations were observed in 8 of 12 specimens after crizotinib failure (G1202R, G1269A, I1171T, L1196M, C1156Y and F1245V). After alectinib failure, G1202R and I1171N mutations were detected in 7 of 15 specimens. G1202R, F1174V and G1202R, and P‐gp overexpression were observed in 3 of 7 samples after ceritinib treatment. L1196M + G1202R, a compound mutation, was detected in 1 specimen after lorlatinib treatment. ALK‐TKI treatment duration was longer in the on‐target treatment group than that in the off‐target group (13.0 vs 1.2 months). In conclusion, resistance to ALK‐TKI based on secondary mutation in this study was similar to that in previous reports, except for crizotinib resistance. Understanding the appropriate treatment matching resistance mechanisms contributes to the efficacy of multiple ALK‐TKI treatment strategies.

show abstract

“…A similar small series investigated crizotinib with alectinib in only 11 patients and delivered a comparable combined mPFS of 18.2 months . An Italian series reported an ORR with second‐line ALKi of 86.4%, analogous with clinical trial data …”

Section: Discussionmentioning

confidence: 60%

Treatment of ALK‐rearranged non‐small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

Itchins

Chia

Hayes

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.

show abstract

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis

Cited by 45 publications

References 25 publications

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

Treatment of ALK‐rearranged non‐small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

Contact Info

Product

Resources

About